Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CUMBERLAND PHARMACEUTICALS INC (CPIX)

Cumberland Pharmaceuticals says ifetroban DMD heart data won't be presented in August 2026

Neutral Impact 2 of 5 other Written later

Cumberland Pharmaceuticals said long-term safety and efficacy data from the open-label extension of its Phase 2 FIGHT DMD trial of ifetroban, an oral therapy for Duchenne muscular dystrophy heart disease, is not yet available. The company no longer expects to present the data in August 2026 and intends to present it at a future date. The filing is a schedule update that gives no new trial results.

Key points

  • The data was previously expected to be presented in August 2026, as shown on a slide at the June 26, 2026 Parent Project Muscular Dystrophy conference in Orlando, Florida.
  • The company says the data is not yet available and no longer expects to present it in August 2026.
  • No new response, safety or efficacy results were disclosed; no future date was given.

The filing

CompanyCUMBERLAND PHARMACEUTICALS INC (CPIX)
Form8-K, current report
Filed with the SECAug 28, 2026, 5:08 PM ET
Accession number0001087294-26-000064

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.